Hepatocellular Cancer

This page contains recent news articles, when available, and an overview of Hepatocellular Cancer but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Hepatocellular Cancer

BioSphere Medical Reports Third Quarter Revenue of $7.69 Million and a ...  -  ‎Oct 28, 2009‎
ReutersOnly about 25% of the more than 600000 patients diagnosed each year with hepatocellular cancer worldwide can be treated with surgical resection or a liver ...

Transplantation and Treatment of Liver Disease at Einstein  -  ‎Nov 5, 2009‎
Physicians News DigestEinstein's multidisciplinary liver cancer team meets weekly for a Hepatocellular Carcinoma Conference to discuss and develop a management care plan for each ...

A proteomic strategy to identify novel serum biomarkers for liver ...  -  ‎Aug 5, 2009‎
7thSpace Interactive (press release)Affected individuals are at risk of developing both cirrhosis and hepatocellular cancer (HCC). Presently there is no cost effective population based means

NICE To Meet Again To Discuss Final Appraisal Determination Of ...  -  ‎Jul 22, 2009‎
Medical News Today (press release)...to work with the NICE and the Department of Health through this delay, to secure access to Nexavar for NHS patients with advanced hepatocellular cancer.

UK ExpressThe drug, which is widely available in Europe, is the first to have worked in the case of hepatocellular cancer. Dr Harpreet Wasan, a cancer consultant at

Risk of Needle Track Seeding Following Biopsy for HCC is 2.7%  -  Oct 30, 2008
Cancer Consultants,Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut.

Meta-analysis Defines Risk of Needle Track Seeding Following ...  -  Nov 3, 2008
Cancer Consultants,Researchers from the UK have reported that the risk of needle track seeding following biopsy of hepatocellular cancer (HCC) is approximately 3%.

Sexagenarian liver cancer rate dips sharply  -  Oct 29, 2008
The Daily Yomiuri,Hepatocellular cancer sufferers account for 95 percent of those diagnosed with liver cancer. About 75 percent of cases of this form of liver cancer is said

Human Genome Sciences Inc. Q3 2008 Earnings Call Transcript  -  Nov 6, 2008
Seeking Alpha,...trials those being in hepatocellular cancer and multiple myeloma, will support a decision on whether to advance HGS-ETR1 into Phase III development.

Mersana takes $4M in new funding  -  Oct 24, 2008
Mass High Tech,He led the team that discovered and advanced Nexavar, an anti-cancer agent that is approved for indications including renal and hepatocellular cancer,

Human Genome Sciences Announces Third Quarter 2008 Financial ...  -  Nov 7, 2008
PharmaLive.com (press release),The results of the NSCLC trial, along with the results of ongoing randomized Phase 2 studies of HGS-ETR1 in advanced hepatocellular cancer and advanced

Cytokinetics Announces Clinical Data Regarding Ispinesib in ...  -  Jun 30, 2008
FOXBusiness...one in the first-line treatment of patients with hepatocellular cancer, one in the first-line treatment of patients with melanoma, one in the first- or

Phase II Study Of IMC-A12 For Advanced Liver Cancer Opens For ...  -  May 16, 2008
Medical News Today (press release),...growth factor-1 receptor (IGF-1R) monoclonal antibody, in patients with advanced hepatocellular cancer (liver cancer) has opened for patient enrollment.

Human Genome Sciences Announces First Quarter 2008 Financial ...  -  May 5, 2008
PR Newswire (press release),Preclinical data that support the hepatocellular cancer study were presented at the American Association for Cancer Research annual meeting in April.

Drug advances boost Human Genome Sciences  -  Apr 30, 2008
Business Gazette,...call that it plans to initiate its phase 2 chemotherapy combination trial of one of the treatments by midyear in patients with hepatocellular cancer.

Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for ...  -  May 13, 2008
Centre Daily Times,...growth factor-1 receptor (IGF-1R) monoclonal antibody, in patients with advanced hepatocellular cancer (liver cancer) has opened for patient enrollment.

Market Report -- In Play (WIRES)  -  May 13, 2008
MSN MoneyIgG1 anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced hepatocellular cancer (has opened for patient enrollment.

Liver Cancer – Signs and Symptoms of Liver Cancer  -  Mar 17, 2008
Los Angeles Chronicle,Thus, the majority of primary liver cancers (over 90 to 95%) arises from liver cells and is called hepatocellular cancer or carcinoma.

Pfizer at Cowen and Company Health Care Conference - Final  -  Mar 24, 2008
Insurance News Net (press release),...situations that where we need to develop our drugs for gastric cancer, for hepatic cancer -- primary hepatocellular cancer and nasopharyngeal cancer.

ntists identify family of liver cancer genes  -  Mar 1, 2008
Thaindian.com,Washington, Mar 2 (ANI): A new study on mice, conducted by an interdisciplinary team of researchers at Stony Brook University Medical Center, has reported

Eisai Enters Into In-licensing Agreement with Minophagen ...  -  Dec 18, 2007
PharmaLive.com (press release),The results of these efforts have led to the introduction of the PIVKA-II series, a diagnosis product for hepatocellular cancer in 1989, which has been

full text  -  Nov 22, 2007
Science Magazine (subscription)93, 1495 (2006). the contributions of sex steroid dysregulation to the development of hepatocellular cancer (hcc) has been debated for decades,

fda approves bayer's nexavar for liver cancer  -  Nov 19, 2007
eFluxMedia...by alice turner the us food and drug administration has approved a previously "fast track"-designated drug for treatment of advanced hepatocellular

vaxon biotech receives european orphan medicinal product ...  -  Nov 21, 2007
Checkbiotech.org (press release),...two product candidates are in clinical development: vx-001 is pursuing phase ii studies in non-small cell lung cancer (nsclc) and hepatocellular cancer,

northwestern university and acorn commence national enrollment for ...  -  Nov 12, 2007
Earthtimes,...researchers are studying nexavar in pivotal trials in hepatocellular cancer, metastatic melanoma and non-small cell lung cancer. northwestern university

A Tumor Marker Ca 19-9 In Diabetics Can Lead To Misdiagnosis Of ...  -  Oct 15, 2007
Science Daily (press release)...ovarian cancer, hepatocellular cancer, colorectal cancer, inflammatory conditions of the hepatobiliary system, and in thyroid diseases.

Eloxatin® and Xeloda® for Treatment of Advanced Hepatocellular ...  -  Oct 10, 2007
Cancer Consultants (press release),Researchers from France have reported that the combination of Eloxatin (oxaliplatin) and Xeloda (Xelox®, capecitabine) is effective for the treatment of

Background information on Hepatocellular Cancer [When available]

Hepatocellular carcinoma (HCC, also called hepatoma or liver cancer) is a primary malignancy (cancer) of the liver. Most cases of HCC are secondary to either hepatitis infection (usually hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis). In countries where hepatitis is not endemic, most cancers in the liver are not primary HCC but metastasis (spread) of cancer from elsewhere in the body, e.g. the colon. Treatment options of HCC and prognosis are dependent on many factors but especially on tumor size and staging.

In Sub-Saharan Africa and most other Third World countries the commonly accepted prognosis is a median survival of 3 months from diagnosis. This is partially due to late presentation with large tumours, but also the lack of medical expertise and facilities.

Search the web for more resources on Hepatocellular Cancer

Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

The Cancer News Network


Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

We will do our best to accommodate your request.